title: Optimal management of esophageal adenocarcinoma: should we be CROSS?
authors: Royal Marsden Hospital, Sutton, United Kingdom elizabeth.smyth@rmh.nhs.uk.
authors: Elizabeth C
authors: EC
authors: Smyth
authors: Royal Marsden Hospital, Sutton, United Kingdom.
authors: Tom S
authors: TS
authors: Waddell
authors: Royal Marsden Hospital, Sutton, United Kingdom.
authors: David
authors: D
authors: Cunningham
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000628:therapy*; D016629:Esophagectomy; D004943:Esophagogastric Junction; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D013274:Stomach Neoplasms / Q000628:therapy*